CANBERA (dpa-AFX) - Australian biotech company CSL Ltd. (CSL.AX, CMXHF.PK) Wednesday said its full-year profit after tax rose to $1.379 billion from $1.307 billion in the previous year. Earnings per basic share grew to $2.92 from $2.70.
Adjusted net profit totaled $1.401 billion in the just concluded year.
Total revenue rose to $5.613 billion from last year's $5.504 billion.
CSL expects strong underlying demand for its products to continue in fiscal year 2016, with sales growth similar to gains achieved in the prior year. The company said the market place would remain competitive, particularly as new manufacturers and products emerge.
Copyright RTT News/dpa-AFX